Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives
Vaccines · 28.02.2026 · 14 (3) · 221
DOI: 10.3390/vaccines14030221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 28.02.2026. Verfasst von Kyung Hyun Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center, Rznomics Inc., Seongnam 13486, Republic of Korea. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Bio & Medical Technology Development Program of the National Research Foundation.
Abstract (Originalsprache)
Circular RNA (circRNA) has emerged as an alternative RNA modality for vaccine development due to its covalently closed structure and enhanced molecular stability compared with linear messenger RNA (mRNA). Following the clinical success of mRNA vaccines, circRNA-based platforms have gained attention in both prophylactic and cancer immunization. Unlike linear mRNA, circRNA relies on cap-independent translation and is commonly produced through in vitro transcription coupled with ribozyme-mediated self-circularization. In prophylactic vaccination, circRNA vaccines have demonstrated sustained antigen availability, robust humoral and cellular immune responses, and flexibility in multivalent designs and targeted delivery strategies that support germinal center reactions and neutralizing antibody generation. In cancer vaccines, circRNA has been applied to tumor-associated antigens, neoantigens, and non-canonical peptides, with a primary focus on inducing potent antigen-specific CD8+ T cell immunity and enabling combination immunotherapy approaches. This review summarizes recent applications of circRNA-based vaccines in prophylactic and cancer settings, emphasizing in vitro transcription-compatible self-circularization strategies and discussing how methodological choices in RNA design, translation control, purification, and delivery shape immunological outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- R&D Center, Rznomics Inc., Seongnam 13486, Republic of Korea.
- Department of Bioconvergence Engineering, Research Institute of Advanced Omics, Dankook University, Yongin 16890, Republic of Korea.
ORCID-Profile: Kyung Hyun Lee, Seong-Wook Lee
Förderung
- National Research Foundation of Korea
- Bio & Medical Technology Development Program of the National Research Foundation
Zitieren
APA
Lee, K. H., Lee, J., & Lee, S. W. (2026). Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives. Vaccines, 14(3), 221. https://doi.org/10.3390/vaccines14030221
Vancouver
Lee KH, Lee J, Lee SW. Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives. Vaccines. 2026;14(3):221. doi:10.3390/vaccines14030221
BibTeX
@article{Lee2026,
author = {Lee, Kyung Hyun and Lee, Jaejin and Lee, Seong-Wook},
title = {Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {3},
pages = {221},
doi = {10.3390/vaccines14030221}
}
EUVIMED